18319-92-1

Basic information

• Product Name: 4-METHYLUMBELLIFERYL HEPTANOATE
• Synonyms: HEPTANOIC ACID 4-METHYLUMBELLIFERYL ESTER;4-METHYLUMBELLIFERYL ENANTHATE;4-METHYLUMBELLIFERYL HEPTANOATE;4-MU-HEPTANOATE;heptanoicacid,4-methyl-2-oxo-2h-1-benzopyran-7-ylester;4-methyl-2-oxo-2H-1-benzopyran-7-yl heptanoate;4-METHYLUMBELLIFERYL ENANTHATE, FOR FLUO RESCENCE;4-MethylumbelliferylHeptanoateA.R.
• CAS NO: 18319-92-1
• Molecular Formula: C₁₇H₂₀O₄
• Molecular Weight: 288.34
• EINECS: 242-207-0
• Product Categories: Pharmaceutical Raw Materials;Substrates;substrate
• Mol File: 18319-92-1.mol
• Article Data: 2

Chemical Properties

• Melting Point: 41-42 °C(lit.)
• Boiling Point: 429°Cat760mmHg
• Flash Point: 214.5°C
• Appearance: /
• Density: 1.129g/cm³
• Vapor Pressure: 1.45E-07mmHg at 25°C
• Refractive Index: 1.531
• Storage Temp.: −20°C
• BRN: 1256801
• CAS DataBase Reference: 4-METHYLUMBELLIFERYL HEPTANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHYLUMBELLIFERYL HEPTANOATE(18319-92-1)
• EPA Substance Registry System: 4-METHYLUMBELLIFERYL HEPTANOATE(18319-92-1)

Safety Data

• WGK Germany: 3
• F: 8-10-21
• Hazardous Substances Data: 18319-92-1(Hazardous Substances Data)

Usage

Description

4-METHYLUMBELLIFERYL HEPTANOATE is a white solid that is commonly utilized in various applications due to its unique chemical properties. It is known for its ability to serve as a biological indicator of sterilization and as a fluorogenic substrate for lipases, making it a valuable compound in different industries.

Uses

Used in Sterilization Industry:
4-METHYLUMBELLIFERYL HEPTANOATE is used as a biological indicator for sterilization processes. It helps to ensure the effectiveness of sterilization methods by providing a visual confirmation of successful sterilization, which is crucial for maintaining the safety and quality of medical equipment and supplies.
Used in Pharmaceutical and Biotechnology Industry:
4-METHYLUMBELLIFERYL HEPTANOATE is used as a fluorogenic substrate for lipases. This application is particularly important in the pharmaceutical and biotechnology industries, where it aids in the study and development of lipase enzymes and their potential therapeutic applications. The compound's ability to fluoresce upon enzymatic cleavage allows for the easy detection and quantification of lipase activity, facilitating research and drug development processes.

InChI:InChI=1/C17H20O4/c1-3-4-5-6-7-16(18)20-13-8-9-14-12(2)10-17(19)21-15(14)11-13/h8-11H,3-7H2,1-2H3

Upstream product

• 5980-33-6 sodium 4-methylumbelliferonate 
• 2528-61-2 Heptanoic acid chloride 
• 90-33-5 7-hydroxy-4-methyl-chromen-2-one 

Downstream Products

• 90-33-5 7-hydroxy-4-methyl-chromen-2-one 
• 111-14-8 oenanthic acid 

Related news

Evaluation of 4-METHYLUMBELLIFERYL HEPTANOATE (cas 18319-92-1) as a substrate for oat lipase08/19/2019

The fluorogenic substrate 4-methylumbelliferyl heptanoate (MUH) has been reported to be suitable for measurement of lipase activity in cereal grains. In the present study, MUH hydrolysis was compared with a conventional lipase assay which measured the release of free fatty acids (FFA) from endog...detailed

Relevant articles and documents

Anti-influenza drug discovery: Structure-activity relationship and mechanistic insight into novel angelicin derivatives

By using a cell-based high throughput screening campaign, a novel angelicin derivative 6a was identified to inhibit influenza A. (H1N1) virus induced cytopathic effect in Madin-Darby canine kidney cell culture in low micromolar range. Detailed structure-activity relationship studies of 6a revealed that the angelicin scaffold is essential for activity in pharmacophore B, while meta-substituted phenyl/2-thiophene rings are optimal in pharmacophore A and C. The optimized lead 4-methyl-9-phenyl-8-(thiophene-2-carbonyl)-furo[2,3-h] chromen-2-one (8g, IC50 = 70 nM) showed 64-fold enhanced activity compared to the high throughput screening (HTS) hit 6a. Also, 8g was found effective in case of influenza A (H3N2) and influenza B virus strains similar to approved anti-influenza drug zanamivir (4). Preliminary mechanistic studies suggest that these compounds act as anti-influenza agents by inhibiting ribonucleoprotein (RNP) complex associated activity and have the potential to be developed further, which could form the basis for developing additional defense against influenza pandemics.